Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-TRP

a technology of beta-trp and composition, which is applied in the field of methods and compositions for treating and diagnosing diabetes and related diseases involving beta-trp, can solve the problems of hyperglycemia (abnormally high level of glucose in the blood), not all patients with high levels of these antibodies develop iddm, and decrease the amount of secreted insulin, so as to induce glucose-stimulated insulin production, enhance the expression or activity of polypeptides, and enhance the effect o

Inactive Publication Date: 2007-02-08
METABOLEX INC
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As these cells are progressively destroyed, the amount of secreted insulin decreases, eventually leading to hyperglycemia (abnormally high level of glucose in the blood) when the amount of secreted insulin drops below the level required for euglycemia (normal blood glucose level).
However, not all patients with high levels of these antibodies develop IDDM.
This failure to respond (called insulin resistance) may be due to reduced numbers of insulin receptors on these cells, or a dysfunction of signaling pathways within the cells, or both.
As discussed above, one of the principal underlying causes of diabetes is the inability of beta cells to produce sufficient insulin to maintain glucose levels.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-TRP
  • Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-TRP
  • Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-TRP

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0182] This example demonstrates that βTRP is expressed in pancreatic islet cells and demonstrates that introduction of βTRP into islet cells of diabetic animals improves glucose stimulated insulin secretion.

[0183] Custom Affymetrix™ oligonucletide arrays were used to survey islet gene expression. Microarray probe set MBXRATISLI2881 was called “Present” by the Affymetrix GeneChipTm analysis software in 5 independent rat islet mRNA samples and absent in 10 other tissues examined. The mouse probe set MBXMUSISL22609 also demonstrated a high degree of enrichment in islets and in the cultured beta cell line (betaHC9) mRNA samples relative to those of other tissues (FIG. 1B). Multiple clones for the corresponding cDNAs were found in human, rat and mouse islet libraries, and sequencing of these revealed that the encoded protein was a predicted TRP channel, which we named betaTRP. The human gene for betaTRP had been sequenced as part of an examination of the Beckwith-Wiedeman syndrome locu...

example 2

[0186] This example demonstrates methods for high throughput screening of modulators of βTRP.

[0187] Activation (opening) of the pancreatic β cell cation channel βTRP represents a novel mechanism for enhancing glucose-stimulated insulin secretion in individuals with type II diabetes. Type II diabetes results when pancreatic beta cells are unable to compensate for the increased insulin demand caused by peripheral insulin resistance. Therapeutic agents such as sulphonylureas and meglitinides promote insulin secretion via the same molecular mechanism (KATP channel closure) as the major pathway by which glucose regulates insulin secretion. Although these agents are widely used, they can be less than ideal in that they have intrinsic potential to cause hypoglycemia and also have significant rates of primary and secondary failure. Activation of mechanisms in the β cell that do not in themselves trigger insulin secretion but potentiate Ca++ influx after glucose-dependent KATP channel closu...

example 3

[0219] This Example demonstrates solvent dose responses and responses to other channel modulators.

[0220] Effect of DMSO

[0221] In the FLEXStation assay, upon the addition of the testing compound (a 25 μl of compound solution was added to each well which contains 100 μl of diluted dye) the CHO-βTRP cells tend to lose some intensity of fluorescent signal. The drop in RFU signal was indistinguishable between the assay buffer and low concentration of DMSO (<0.5%), but was significantly exaggerated by 2.5% DMSO (FIG. 5). On the other hand, we did not observe any non-specific depolarization responses to DMSO.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Tmaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to view more

Abstract

Expression of beta-TRP is enriched in islet cells. Introduction of expression cassettes encoding beta-TRP into diabetic islet cells improved glucose-stimulated insulin production. Therefore, the invention provides methods of identifying beta-TRP modulators for treating diabetic individuals and introducing beta-TRP into islet cells

Description

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS [0001] The present application claims benefit of priority to U.S. Provisional Patent Application No 60 / 452,596, filed Mar. 5, 2003, which is incorporated by reference in its entirety for any purpose.BACKGROUND OF THE INVENTION [0002] Diabetes mellitus can be divided into two clinical syndromes, Type 1 and Type 2 diabetes mellitus. Type 1, or insulin-dependent diabetes mellitus (IDDM), is a chronic autoimmune disease characterized by the extensive loss of beta cells in the pancreatic Islets of Langerhans, which produce insulin. As these cells are progressively destroyed, the amount of secreted insulin decreases, eventually leading to hyperglycemia (abnormally high level of glucose in the blood) when the amount of secreted insulin drops below the level required for euglycemia (normal blood glucose level). Although the exact trigger for this immune response is not known, patients with IDDM have high levels of antibodies against pancreatic ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/567C07H21/04C07K14/575A61K48/00C07K14/705C12Q1/68G01N33/50G01N33/53G01N33/68G01N33/74
CPCA61K48/00C07K14/705G01N33/507G01N2333/62G01N33/6872G01N33/74G01N33/5088A61P5/50A61P3/10
Inventor JOHNSON, JEFFREY D.ZHOU, YUN-PING
Owner METABOLEX INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap